Anvisa Launches Certification Initiative to Boost Domestic Pharmaceutical Ingredient Production
The agency will select eight dossiers to strengthen local manufacturing and reduce foreign dependency.
1New Certification Initiative
Anvisa has announced a program to certify domestically produced Active Pharmaceutical Ingredients, known as IFAs. The agency will select up to eight dossiers for evaluation, regardless of their current status in medication registration petitions. This initiative aims to bolster the national health industrial complex by reducing reliance on foreign suppliers.
2Eligibility Criteria Defined
To participate, companies must hold dossiers for IFAs manufactured within Brazil. The production process must include at least the final stage of chemical synthesis locally. Furthermore, manufacturers are required to possess a valid Certificate of Good Manufacturing Practices, which is an essential regulatory document issued directly by the Anvisa agency.
3Selection Process Details
The selection process prioritizes substances listed in the official public notice. Anvisa will evaluate candidates based on their contribution to national development, involvement in public research and innovation programs, and the extent of production stages completed within Brazil. These criteria ensure that the selected projects align with broader industrial health goals.
4Application and Timeline
Interested companies must submit their applications via an electronic form within 60 calendar days from the publication date. Following the submission period, the agency will announce the results within another 60-day window. The actual technical analysis of the chosen dossiers is scheduled to take place throughout the year 2027.
5Defining Active Ingredients
Active Pharmaceutical Ingredients, or IFAs, represent the foundational stage of the pharmaceutical supply chain. These raw materials provide the specific therapeutic characteristics that allow a medication to function effectively. Anvisa maintains strict oversight, acting as the primary authority responsible for the sanitary control and fiscal inspection of these critical substances.
6Strategic Industrial Goals
By fostering local production, the government seeks to stabilize the pharmaceutical supply chain against global market volatility. This move is part of a larger effort to develop the Economic-Industrial Health Complex. Strengthening domestic capacity is viewed as a mechanism to ensure consistent access to essential medicines for the Brazilian population.
7Regulatory Oversight Mechanism
The issuance of a Letter of Adequacy for the IFA dossier serves as a formal validation of quality standards. Anvisa ensures that all participants adhere to rigorous regulatory requirements throughout the evaluation cycle. This process maintains the integrity of the pharmaceutical market while encouraging local firms to upgrade their manufacturing capabilities.
8Future Industry Impact
The success of this initiative will be measured by the ability of local firms to meet international quality standards while scaling production. As the 2027 analysis period approaches, the industry expects a clearer roadmap for domestic ingredient self-sufficiency. This program marks a shift toward prioritizing local innovation in health manufacturing.